Asahi Kasei Makes $1.1B Offer For Swedish Drugmaker Calliditas Therapeutics, Enhancing Pharma Growth Strategy
Portfolio Pulse from Vandana Singh
Asahi Kasei Corporation has made a $1.1 billion offer to acquire Swedish pharmaceutical company Calliditas Therapeutics AB (NASDAQ:CALT). The deal, which offers 208 Swedish krona per share and 416 Swedish krona per ADS, has been unanimously recommended by the Calliditas board. This acquisition aims to enhance Asahi Kasei's global pharmaceutical growth strategy, particularly in the U.S. market, by leveraging Calliditas' lead product, Tarpeyo, for IgA nephropathy.
May 28, 2024 | 4:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Asahi Kasei's $1.1 billion offer for Calliditas Therapeutics has led to a 70% increase in CALT shares. The acquisition aims to enhance Asahi Kasei's global pharmaceutical strategy, particularly in the U.S. market.
The acquisition offer from Asahi Kasei has been unanimously recommended by the Calliditas board, indicating a high likelihood of the deal going through. This has resulted in a significant 70% increase in CALT shares, reflecting strong investor confidence.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100